Abstract

Dr. Bhargav Raj MS*, Dr. Sandhya Appachu, Dr. Prathyush Vundemodalu and Dr. Manasa C.

ABSTRACT

Cyclin-dependent kinase 4 and 6 inhibitors have emerged as pivotal targeted therapies for hormone receptor-positive breast cancer. While bone marrow suppression and gastrointestinal toxicities are well-documented adverse effects, cutaneous reactions remain underreported. This case report presents a 64-year-old patient with breast cancer who developed cutaneous rashes upon initiating abemaciclib, confirmed through a skin biopsy revealing eosinophilic infiltration, indicative of a probable drug-induced etiology. Despite the rarity of such events, their impact on patient quality of life and treatment discontinuation warrants attention. The case contributes to the limited literature on skin-related adverse events associated with CDK 4/6 inhibitors, emphasizing the importance of recognizing and managing these less common yet impactful reactions. As targeted anticancer therapies become more prevalent, comprehensive monitoring and early intervention are crucial for optimizing patient outcomes. This report aims to raise awareness within the medical community and enhance proactive management strategies for cutaneous manifestations linked to abemaciclib.